Home Newsfeeds Wedbush Upgrades FuboTV to Outperform

Wedbush Upgrades FuboTV to Outperform

Wedbush analyst Michael Pachter upgrades FuboTV (NYSE:FUBO) from Neutral to Outperform.

byBenzinga Newsdesk

September 23, 2022

1 minute read

Wedbush analyst Michael Pachter upgrades FuboTV (NYSE:FUBO) from Neutral to Outperform.

Microbot Medical Successfully Completes An Extensive Pre-Clinical Study Performed In The U.S.

By Happy Mohamed

June 29, 8:37 AM

Microbot Medical Inc. (NASDAQ:MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced the successful completion of an extended

MBOT

Analyst Ratings

What 4 Analyst Ratings Have To Say About Mustang Bio

By Benzinga Insights

August 15, 12:00 PM

Analysts have provided the following ratings for Mustang Bio (NASDAQ:MBIO) within the last quarter: Bullish Somewhat Bullish Indifferent…

MBIO

Pasithea Therapeutics Announces Invention Of Crystalline Form Of PAS-004; Establishes Strengthened Intellectual Property Position

By Benzinga Newsdesk

January 8, 9:00 AM

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio --SOUTH SAN FRANCISCO, Calif. and

KTTA

PDS Biotech Announces PDS0101 Combined With Chemoradiotherapy Associated With Rapid Decline In Circulating Tumor DNA (ctDNA/cfDNA)

By Benzinga Newsdesk

October 2, 8:06 AM

Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) treatmentPatients

PDSB

Wedbush Upgrades FuboTV to Outperform

Related Posts

Microbot Medical Successfully Completes An Extensive Pre-Clinical Study Performed In The U.S.

What 4 Analyst Ratings Have To Say About Mustang Bio

Pasithea Therapeutics Announces Invention Of Crystalline Form Of PAS-004; Establishes Strengthened Intellectual Property Position

PDS Biotech Announces PDS0101 Combined With Chemoradiotherapy Associated With Rapid Decline In Circulating Tumor DNA (ctDNA/cfDNA)